antiviral and associated therapy living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 all comers	COVID-19 mild to moderate	COVID-19 severe or critically

	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate	COVID-19 severe or critically
antiviral and associated therapy
azithromycin	Sekhavati RECOVERY ...		COALITION I Covid-19 Brazil ... Rashad A ...	COALITION II Covid-19 Brazil ...
azvudine			Ren
baloxavir marboxil	Lou Y
bromhexine	Ansarin Tolouian		Li T
chloroquine and derivatives
chloroquine	Huang	Chen, ChiCTR2000030054 - Chloroquine	NCT04342650
hydroxychloroquine	Tang HAHPS ORCHID Duke University hydroxychloroquine/azithromycine RECOVERY SOLIDARITY ... Chen NO COVID-19 ... Abd-Elsalam CCAP-1 Duke university HCQ ARCHAIC -hydroxychloroquine PROTECT B TEACH OAHU-COVID19 HYCOVID IRCT20200428047228N1 // U07 Gonzalez ... PROTECT A	ChiCTR2000030054-HCQ ... IRCT20150808023559N20 IRCT20150808023559N20 NOR-Solidarity ...	HC-nCoV ... Zhaowei Chen Coalition Covid-19 Brazil I ... NCT04333654 FACCT Trial Dubee Kamran	REMAP-CAP-HCQ HYDRA ... Sarhan Sarhan
darunavir cobicistat		Jun C
Emtricitabine/tenofovir plus colchicine plus rosuvastatin	Gaitan-Duarte ...
Ensitrelvir (XOCOVA)			Mukae - Phase 2a
favipiravir	IRCT20200428047228N1 // U07 Udwadia AVIFAVIR	Lou ... Chang Chen et al. NCT04310228-FAVI ... jRCTs041190120 IRCT20150808023559N20 IRCT20150808023559N20	Dabbous HM Holubar M IRCT20151227025726N14 // U07 FACCT Trial Udwadia AVIFAVIR Shenoy S NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai
favipiravir plus interferon			Khamis
hydroxychloroquine plus macrolides	Duke university HCQ-AZI
azithromycin plus hydroxychloroquine	ProPAC-COVID		Coalition Covid-19 Brazil I ...
ivermectin	Gonzalez ...		Shahbaznejad Ahmed Chachar Chaccour Bukhari Kirti Babalola RIVET-COV ... Abd-Elsalam Krolewiecki I-TECH ... Mayer	Okumuş Galan Galan
ivermectin plus doxycycline	Hashim A		NCT04523831 ...
lopinavir/ritonavir	RECOVERY SOLIDARITY ... Nojomi Ader ...		ELACOI ...	Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine				REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a	Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b			Hung et al.
niclosamide	Abdulamir
nirmatrelvir / ritonavir (Paxlovid)		EPIC-SR
nitazoxanide			Rocco Silva Fontanesi
opaganib	Winthrop
remdesivir	NIH NIAID ACTT-1 DisCoVeRy ... SOLIDARITY ... Mahajan	Norwegian NOR study ... Andreas ...	GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...	CAP-China ...
sofosbuvir	Sali Alavi-moghaddam
sofosbuvir and daclatasvir	Sadeghi Yakoot Mobarak S ... Mobarak ...
sofosbuvir and ledipasvir	Elgohary		Nourian A
tenofovir/emtricitabine	Gaitan-Duarte ...
umifenovir (arbidol)	UAIIC Nojomi	ELACOI ...	Yethindra ELACOI ...
zinc	Patel

48 studies excluded by filtering options 1

4861	Cai -FAVIPIRAVIR, 2020	1	31	0		not a RCT	risk of bias not avaialble
4905	ChiCTR2000029975, 0	2	30	0	excluded	not a RCT	risk of bias not avaialble
5209	SIMPLE (Grein), 0	2	30	0	excluded	not a RCT	risk of bias not avaialble
5210	Ye et al., 2020	2	99	0	excluded	not a RCT	risk of bias not avaialble
5288	Barbosa, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5314	Magagnoli (HC AZ), 2020	1	13	3		not a RCT	high risk of bias
5351	Mallat, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5365	Rosenberg, 2020	1	13	3		not a RCT	high risk of bias
5365	Rosenberg, 2020	1	13	3		not a RCT	high risk of bias
5365	Rosenberg, 2020	1	13	3		not a RCT	high risk of bias
5371	Carlucci, 2020	0	13	4	selection pending
5375	Mehra, 2020	2	13	3	excluded	not a RCT	high risk of bias
5375	Mehra, 2020	2	13	3	excluded	not a RCT	high risk of bias
5482	Sbidian (HCQ plus AZI), 2020	1	13	4		not a RCT	high risk of bias
5490	Kurd, 2020	0	10	0	selection pending
5509	Lagier, 2020	1	13	4		not a RCT	high risk of bias
5513	Arshad (HCQ AZ), 2020	1	13	4		not a RCT	high risk of bias
5546	remdesevir external control, 0	0	13	0	selection pending
5559	Davido, 2020	1	13	4		not a RCT	high risk of bias
5599	Karolyi, 2020	0	13	0	selection pending
6034	Huang, 2020	0	99	0	selection pending
6064	Glorial F, 2020	1	10	0		not a RCT	risk of bias not avaialble
6082	ICON, 2020	0	13	0	selection pending
6095	Camprubi, 2020	1	11	0		not a RCT	risk of bias not avaialble
6184	Erdem, 2020	2	11	0	excluded	not a RCT	risk of bias not avaialble
6252	NCT04376814-Group A, 2020	0	31	0	selection pending
6262	Yamamura, 2020	2	30	0	excluded	not a RCT	risk of bias not avaialble
6263	Calik, 2020	1	10	4		not a RCT	high risk of bias
6267	Murohashi, 2020	2	10	0	excluded	not a RCT	risk of bias not avaialble
6287	Kocayigit H, 2020	1	10	0		not a RCT	risk of bias not avaialble
6332	Rodriguez-Molinero, 2020	1	10	0		not a RCT	risk of bias not avaialble
6375	Cadegiani -Iver, 2020	2	99	0	excluded	not a RCT	risk of bias not avaialble
6381	Espitia-Hernandez, 2020	1	31	0		not a RCT	risk of bias not avaialble
6381	Espitia-Hernandez, 2020	1	31	0		not a RCT	risk of bias not avaialble
6382	Khan, 2020	0	13	0	selection pending
6382	Khan, 2020	0	13	0	selection pending
6383	Soto-Becerra, 2020	0	12	2	selection pending
6383	Soto-Becerra, 2020	0	12	2	selection pending
6384	Spoorthi, 2020	1	31	0		not a RCT	risk of bias not avaialble
6384	Spoorthi, 2020	1	31	0		not a RCT	risk of bias not avaialble
6384	Spoorthi, 2020	1	31	0		not a RCT	risk of bias not avaialble
6384	Spoorthi, 2020	1	31	0		not a RCT	risk of bias not avaialble
6516	Eslami, 2020	1	31	0		not a RCT	risk of bias not avaialble
6625	Nasir, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
6749	Chen_oseltamivir, 2020	1	13	4		not a RCT	high risk of bias
6750	Chen_arbidol, 2020	1	13	4		not a RCT	high risk of bias
6751	Chen_lopi_rito, 2020	1	13	4		not a RCT	high risk of bias
7995	Hazan, 2021	2	32	0	excluded	not a RCT	risk of bias not avaialble